Chemist + Druggist is part of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Three strengths of olanzapine among final July price concessions

The Department of Health and Social Care and the National Assembly for Wales have agreed on concessionary prices for the following 15 items for July 2020 prescriptions.

An initial 18 price concessions were announced for the month on July 17. A further 8 items were added to the list last week (July 29).

Drug
Strength
Form
Price
Clonidine
25microgram
tablets (112)
£16.99
Enalapril
20mg
tablets (28)
£4.82
Irbesartan
150mg
tablets (28)
£8.09
Metronidazole
400mg
tablets (21)
£4.19
Moxonidine
200microgram
tablets (28)
£9.72
Moxonidine
300microgram
tablets (28)
£2.58
Moxonidine
400microgram
tablets (28)
£9.69
Olanzapine
10mg
tablets (28)
£2.33
Olanzapine
20mg
tablets (28)
£7.87
Olanzapine
5mg
tablets (28)
£2.38
Rasagiline
1mg
tablets (28)
£11.83
Senna
7.5mg
tablets (60)
£2.48
Senna
7.5mg/5ml
oral solution sugar free (500ml)
£10.61
Tacrolimus
0.10%
ointment (30g)
£24.28
Tacrolimus
0.10%
ointment (60g)
£44.45

Do these prices reflect what you've paid so far?

Related Content

Topics


         
Accreditation & Recognition Panel Members
Nationwide
£ Remuneration

Apply Now
UsernamePublicRestriction

Register

CD006646

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel